Skip to main content

Stephanie Holland

Conference Coverage
11/14/2024
Conducting new patient visits via telehealth with advanced practice providers allows for quicker identification, assessment, and surveillance of patients with monoclonal gammopathy of undetermined significance at increased risk of developing...
Conducting new patient visits via telehealth with advanced practice providers allows for quicker identification, assessment, and surveillance of patients with monoclonal gammopathy of undetermined significance at increased risk of developing...
Conducting new patient visits...
11/14/2024
APP Institute Oncology
News
11/14/2024
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the...
11/14/2024
Oncology
News
11/13/2024
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2...
11/13/2024
Oncology
News
11/12/2024
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from...
11/12/2024
Oncology
News
11/06/2024
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a...
11/06/2024
Oncology
News
11/05/2024
Results from the phase 2 SWOG S1011 study demonstrated that extended lymphadenectomy failed to improve survival compared to standard lymphadenectomy among patients with localized muscle-invasive bladder cancer.
Results from the phase 2 SWOG S1011 study demonstrated that extended lymphadenectomy failed to improve survival compared to standard lymphadenectomy among patients with localized muscle-invasive bladder cancer.
Results from the phase 2 SWOG...
11/05/2024
Oncology
News
11/04/2024
According to results from a real-world comparison study, first-line durvalumab plus platinum-doublet chemotherapy prolonged survival compared to first-line atezolizumab plus platinum-doublet chemotherapy for patients with extensive-stage...
According to results from a real-world comparison study, first-line durvalumab plus platinum-doublet chemotherapy prolonged survival compared to first-line atezolizumab plus platinum-doublet chemotherapy for patients with extensive-stage...
According to results from a...
11/04/2024
Oncology
News
12/14/2023
According to post-trial follow-up results from the ASTRRA trial, adjuvant tamoxifen plus ovarian function suppression significantly improved DFS rate with no negative impact on OS among premenopausal patients with pretreated estrogen...
According to post-trial follow-up results from the ASTRRA trial, adjuvant tamoxifen plus ovarian function suppression significantly improved DFS rate with no negative impact on OS among premenopausal patients with pretreated estrogen...
According to post-trial...
12/14/2023
Oncology
Conference Coverage
06/19/2023
Data from a phase 1 trial show that combined treatment with fianlimab plus cemiplimab exhibits high clinical activity and tolerable safety in advanced melanoma, consistent with other approved combinations of immune checkpoint inhibitors in...
Data from a phase 1 trial show that combined treatment with fianlimab plus cemiplimab exhibits high clinical activity and tolerable safety in advanced melanoma, consistent with other approved combinations of immune checkpoint inhibitors in...
Data from a phase 1 trial show...
06/19/2023
Oncology
FDA Approval
01/20/2024
Based on results from cohort 1 of the BLC3001 study, the FDA has approved erdafitinib for patients with locally advanced/metastatic urothelial carcinoma harboring FGFR3 alterations.
Based on results from cohort 1 of the BLC3001 study, the FDA has approved erdafitinib for patients with locally advanced/metastatic urothelial carcinoma harboring FGFR3 alterations.
Based on results from cohort 1...
01/20/2024
Oncology